

Heart failure - Pipeline Insight, 2021

<https://marketpublishers.com/r/H410BC4DD53DEN.html>

Date: July 2021

Pages: 60

Price: US\$ 3,000.00 (Single User License)

ID: H410BC4DD53DEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Heart failure - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Heart failure Understanding

Heart failure: Overview

Heart Failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.

'Heart failure - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure pipeline landscape is provided which includes the disease overview and Heart failure treatment guidelines. The assessment part of the report embraces, in depth Heart failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure.

Heart failure Emerging Drugs Chapters

This segment of the Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart failure Emerging Drugs

Finerenone: Bayer HealthCare Pharmaceuticals

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many of the harmful effects of mineralocorticoid receptor (MR) overactivation. MR overactivation is a major driver of kidney and cardiovascular damage through inflammatory and fibrotic processes. It is in phase III stage of development to treat heart failure.

IONIS-AGT-LRx: Ionis Pharmaceuticals

IONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease. It is in phase II stage of development to treat chronic heart failure.

Further product details are provided in the report.....

Heart failure: Therapeutic Assessment

This segment of the report provides insights about the different Heart failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Heart failure

There are approx. 100+ key companies which are developing the therapies for Heart failure. The companies which have their Heart failure drug candidates in the most advanced stage, i.e. phase III include, Bayer HealthCare Pharmaceuticals.

Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Heart failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure therapeutic drugs key

players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure drugs.

Heart failure Report Insights

Heart failure Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Heart failure Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Heart failure drugs?

How many Heart failure drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Heart failure and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Bayer HealthCare Pharmaceuticals

Ionis Pharmaceuticals

Heartseed Inc.

AstraZeneca

Amgen

Sardocor Corp.

Intra-Cellular Therapies

Bristol Myers Squibb

Eli Lilly and Company

Palatin Technologies

Cardiora

Zensun Sci. & Tech. Co., Ltd.

Biopeutics Co., Ltd

Innolife Co., Ltd.

SQ Innovation

scPharmaceuticals

Mesoblast, Inc

PhaseBio Pharmaceuticals

Salubris Biotherapeutics Inc

Actelion Pharmaceuticals

Torrent Pharmaceuticals Limited

Novo Nordisk A/S

Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.

Merck Sharp & Dohme Corp.

Cardior Pharmaceuticals GmbH

Pfizer

MyoKardia, Inc.

TransThera Biosciences Co., Ltd

Accelaron Pharma Inc.

Asklepios Biopharmaceutical, Inc.

Bial

Key Products

Finerenone

IONIS-AGT-LRx

HS 001

AZD 4831

Omecamtiv Mecarbil

SRD-001

ITI-214

BMS-986259

LY3461767

PL-3994

CRD-102

rhNRG-1

INL1

SQIN-01

Furoscix Infusor

Allogeneic Mesenchymal Precursor Cells (MPC)

PB1046

JK07

Macitentan

TRC041266

Semaglutide

TSG-01

Ertugliflozin

CDR132L

Sildenafil Citrate

Mavacamten

TT-00920

Sotatercept

NAN-101

BIA 5-1058

Contents

Introduction

Executive Summary

Heart failure: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Heart failure – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Heart failure companies' collaborations, Licensing, Acquisition -Deal Value Trends

Heart failure Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Finerenone: Bayer HealthCare Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

IONIS-AGT-LRx: Ionis Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

NAN-101: Asklepios BioPharmaceutical

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

- Comparative Analysis

Drug name: Company name

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Heart failure Key Companies

Heart failure Key Products

Heart failure- Unmet Needs

Heart failure- Market Drivers and Barriers

Heart failure- Future Perspectives and Conclusion

Heart failure Analyst Views

Heart failure Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Heart failure
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Heart failure
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Heart failure - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H410BC4DD53DEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H410BC4DD53DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970